A recent study conducted by researchers at Banaras Hindu University sheds light on the long-term effects of Bharat Biotech’s Covaxin, providing crucial insights into the vaccine’s safety profile. The study, spanning from January 2022 to August 2023, followed 926 participants who received the BBV152 vaccine, comprising 635 adolescents and 291 adults. The findings, published in the journal Springer Nature, reveal significant observations regarding adverse events of special interest (AESI) and their persistence over time.
High Incidence of AESI
According to the study, nearly one-third of the individuals who received Covaxin reported AESI after one year of vaccination. These adverse events encompass a wide range of health issues, with notable prevalence among both adolescents and adults. New-onset skin and subcutaneous disorders, general disorders, and nervous system disorders emerged as the most common AESI among participants. Additionally, menstrual abnormalities were reported in a subset of female participants, alongside ocular abnormalities and hypothyroidism in others.
Serious AESI and Mortality
While the majority of AESI were categorized as non-serious, the study also highlighted the occurrence of serious adverse events, including stroke and Guillain-Barre syndrome, albeit in a small percentage of individuals. Tragically, the study reported four deaths among the adult participants, with stroke and post-COVID-19 rhinocerebral mucormycosis cited as contributing factors. However, the study emphasizes that without a definitive causality association, drawing conclusions regarding the role of Covaxin in these events remains challenging.
Risk Factors and Implications
The study underscores the importance of extended surveillance of COVID-19-vaccinated individuals, particularly those with pre-existing comorbidities or a history of COVID-19 infection. Female individuals and adolescents with pre-vaccination COVID-19 exhibited higher odds of persistent AESI, indicating the need for tailored monitoring and healthcare interventions. Moreover, adults receiving three doses of Covaxin were identified as being at higher risk of AESI compared to those receiving two doses, suggesting a nuanced approach to vaccine administration and follow-up care.
Enhanced Awareness and Vigilance
In light of these findings, the study calls for enhanced awareness and larger-scale studies to comprehensively understand the incidence of immune-mediated phenomena post-COVID-19 vaccination. It stresses the importance of vigilant monitoring and proactive management of adverse events, especially among vulnerable populations. As vaccination campaigns continue worldwide, the insights gleaned from studies like this are invaluable in ensuring the safety and efficacy of vaccines in combating the COVID-19 pandemic.
